Newsletter May 2022 No.209
Top News
The spread of new coronavirus infection (COVID-19) has posed significant challenges to Japan's pharmaceutical industry, including the need to enhance the country's ability to create new drugs and the creation of an innovation environment that will serve as the basis for this. The seminar discussed themes necessary for Japan to continue to be a world-class drug creator, including the development of a drug discovery ecosystem and life science cluster, fostering venture companies and start-ups, strengthening industry-academia-government collaboration, and global mindset. The following is a transcript of the seminar.
Topics
- Report on "Briefing Session on eCTD v4.0 (ICH M8) Notification Revision and Start of Implementation
- 2022 Life Science Intellectual Property Forum" was held at
-COVID-19 Pandemic Findings on the Innovation Ecosystem: Challenges and Prospects for Solutions - Regular meeting with the German Association of the Research-based Pharmaceutical Industry (vfa)" was held
- The 8th Japan-Thailand Joint Symposium" was held
- 2021 Meeting of Compliance Managers and Practitioners in Charge of Compliance Management
- Information Meeting on "Cost-Effectiveness Evaluation System
Policy Research Institute
From JPMA
Creating an Environment for Innovation that Connects with the World